OncoMatch/Clinical Trials/NCT06532643
Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma
Is NCT06532643 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Fludarabine and Cyclophosphamide for relapsed/refractory lymphoma.
Treatment: Fludarabine · Cyclophosphamide — This study is an exploratory clinical trial of a single-center, open-label, single-dose treatment of anti-CD20/CD30-CAR-T cells in subjects with relapsed/refractory lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 positive expression
CD20/CD30 double-positive expressing lymphoma
Required: CD30 positive expression
CD20/CD30 double-positive expressing lymphoma
Required: CD20 positive expression
Relapse after receiving anti-CD19-CAR-T cell therapy, with CD20 positive lymphoma
Required: CD20 positive expression
CD20 positive lymphoma that has not previously received anti-CD19-CAR-T cell therapy
Required: CD30 positive expression
CD30 positive Hodgkin lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy — relapsed/refractory after standard treatments (including allogeneic or autologous hematopoietic stem cell transplantation)
Subjects with refractory or relapsed disease after current standard treatments (including allogeneic or autologous hematopoietic stem cell transplantation) who are not suitable for other treatment options, such as a second stem cell transplant.
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.0×10^9/L; Hemoglobin ≥ 60 g/L (no transfusion in last 7 days); Platelets ≥ 50×10^9/L (unrestricted for CLL indications).
Kidney function
Creatinine < 1.5× ULN and estimated creatinine clearance ≥ 60 mL/min.
Liver function
Total bilirubin ≤ 1.5× ULN; or ≤ 3× ULN when tumor invades liver. AST/ALT ≤ 2.5× ULN, or ≤ 5× ULN when tumor invades liver.
Cardiac function
Ejection fraction ≥ 45%, ECHO confirming no pericardial effusion (excluding small/physiological), ECG with no clinical significance.
Laboratory tests during screening must meet the following requirements... Ejection fraction ≥ 45%, with echocardiogram (ECHO) confirming no pericardial effusion (excluding small or physiological amounts), and electrocardiogram results with no clinical significance.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify